Mucus-penetrating nanoparticles for vaginal drug delivery protect against herpes simplex virus.
about
Mucus penetrating nanoparticles: biophysical tool and method of drug and gene deliveryA holistic approach to targeting disease with polymeric nanoparticlesNanoformulations of Rilpivirine for Topical Pericoital and Systemic Coitus-Independent Administration Efficiently Prevent HIV TransmissionSynthetic Nanoparticles for Vaccines and ImmunotherapyParticle tracking in drug and gene delivery research: State-of-the-art applications and methodsGenital Herpes: Insights into Sexually Transmitted Infectious DiseaseA review of nanotechnological approaches for the prophylaxis of HIV/AIDS.A dense poly(ethylene glycol) coating improves penetration of large polymeric nanoparticles within brain tissue.Nanoparticles that do not adhere to mucus provide uniform and long-lasting drug delivery to airways following inhalation.Vaginal delivery of paclitaxel via nanoparticles with non-mucoadhesive surfaces suppresses cervical tumor growth.Nanoparticle-based drug delivery to the vagina: a review.Controlled release for local delivery of drugs: barriers and models.Pretreatment of human cervicovaginal mucus with pluronic F127 enhances nanoparticle penetration without compromising mucus barrier properties to herpes simplex virusEffect of surface chemistry on nanoparticle interaction with gastrointestinal mucus and distribution in the gastrointestinal tract following oral and rectal administration in the mouse.Minimizing the non-specific binding of nanoparticles to the brain enables active targeting of Fn14-positive glioblastoma cells.Liposome-based mucus-penetrating particles (MPP) for mucosal theranostics: demonstration of diamagnetic chemical exchange saturation transfer (diaCEST) magnetic resonance imaging (MRI).Hyaluronan in cervical epithelia protects against infection-mediated preterm birth.Enema ion compositions for enhancing colorectal drug delivery.Topical Ocular Drug Delivery to the Back of the Eye by Mucus-Penetrating Particles.Biophysical characterization of small molecule antiviral-loaded nanolipogels for HIV-1 chemoprophylaxis and topical mucosal application.Chitosan and Kappa-Carrageenan Vaginal Acyclovir Formulations for Prevention of Genital Herpes. In Vitro and Ex Vivo Evaluation.Effect of Mucosal Cytokine Administration on Selective Expansion of Vaginal Dendritic Cells to Support Nanoparticle Transport.Development and evaluation of a thermosensitive vaginal gel containing raltegravir+efavirenz loaded nanoparticles for HIV prophylaxis.PEG modified liposomes containing CRX-601 adjuvant in combination with methylglycol chitosan enhance the murine sublingual immune response to influenza vaccinationNanoparticle diffusion in respiratory mucus from humans without lung disease.Biomaterial Strategies for Immunomodulation.PEGylation as a strategy for improving nanoparticle-based drug and gene deliveryImpact of Surface Polyethylene Glycol (PEG) Density on Biodegradable Nanoparticle Transport in Mucus ex Vivo and Distribution in Vivo.Ex vivo characterization of particle transport in mucus secretions coating freshly excised mucosal tissues.Scalable method to produce biodegradable nanoparticles that rapidly penetrate human mucusEnhanced vaginal drug delivery through the use of hypotonic formulations that induce fluid uptake.Magnetic Nanodrug Delivery Through the Mucus Layer of Air-Liquid Interface Cultured Primary Normal Human Tracheobronchial Epithelial Cells.Griffithsin-Modified Electrospun Fibers as a Delivery Scaffold To Prevent HIV Infection.Diamond nanogel-embedded contact lenses mediate lysozyme-dependent therapeutic release.Engineering synthetic vaccines using cues from natural immunity.Strategies for improving mucosal drug delivery.Cancer nanomedicine: from drug delivery to imaging.Protein and oligonucleotide delivery systems for vaginal microbicides against viral STIs.Engineering immunity in the mucosal niche against sexually transmitted infections.Enhancing dendritic cell activation and HIV vaccine effectiveness through nanoparticle vaccination.
P2860
Q26823541-466AAF71-EF1E-4AD9-98E6-8AE4BE20C91AQ26865163-E4678355-11CB-4716-BE9C-10DF6A731E22Q27318354-9C7E4E02-E7D6-4FC3-BAEB-E9F9532D5571Q28085375-10BF955D-E0F7-4F11-9128-B6C76FBCA008Q28087396-1FCB27A8-D6A6-4BF5-90F5-44701D30B787Q30235026-2615F1E0-E47F-4BAF-96B6-783859C86F53Q30431343-DAD14E8D-5647-4A57-A1F1-ED9FDBB4BC58Q30541682-DB8DFB4E-E439-434B-83AC-F13E4493F679Q30844270-70D4419D-D205-4F9C-B5BD-3361D4E4133EQ33763847-E7D388B2-4218-4981-925E-88D3CBF17E2EQ34079533-CB7975E0-26D1-40C2-9427-06F5DD4A032AQ34079560-0D112AE8-E99F-4CC4-9CE7-3E57CC0A032BQ34669705-41AC5091-379E-46E5-9C9A-CA3459037B45Q34749181-0B64E8D5-83D2-4C21-B87D-7A1FE0EE6AB0Q34785621-A752A2C1-92AF-45BF-BE61-AE86210C312AQ35088353-4DA33AB5-6192-445E-A464-37B1DCEEF0A1Q35145380-077EDFCF-258F-4296-B32C-4EAC89813E88Q35691007-D1BACB3A-DF16-4C79-9945-31A3E3568D93Q35759073-CD7B7FAF-EF47-44FE-AEBD-9158A5D28D0FQ35947035-2420E21A-FD84-4227-9E9B-4DE5D1147DB3Q36096590-C769944B-4FC9-4ADC-AC7C-2DE2661E455FQ36143091-90AA8139-2031-4D3A-B307-085A7B99527FQ36442232-88264C2E-97A9-49B2-A803-D128E73B8D9FQ36509826-72AF6455-3440-4824-B9A9-CC22D9CA3081Q36664260-7301794E-6EFA-4819-880E-6D5679C7251DQ36703124-FED7314B-0183-4D19-98DC-AE61A27AFC4BQ36703361-DFD656E9-B2B9-4CF0-A9A6-6A3F63DA1782Q36961634-78532D9C-CA06-4F6B-A821-0C031727CF69Q37011581-CDAE8DAC-0E3D-40AA-8725-DFA22D97E02AQ37062353-6C479D84-381D-4E1F-8312-3F222F022211Q37158237-DD197FBA-4CDE-404B-BB4A-2A943720BBD4Q37350756-0A3CD723-A3FE-43FC-9B11-B1DAF809AF71Q37358616-03DADC5C-EAB2-4F7F-8DAC-D19E0377F397Q37731617-7F003CD7-6459-420A-A3BB-1048B16E7342Q38154804-5AF5013A-3F65-4CFF-BACC-29AE7CAB5375Q38166442-DAB0996B-BC1A-42DA-88D5-B4D005F3CA80Q38172476-9506A529-D984-4B96-BDFF-78A33CF8D456Q38260862-B45A4729-D94C-4BF7-93E3-50F08D5B3AC0Q38543768-6CD7EAB6-2C42-4782-8379-4C5B1EAA9C84Q38702368-BE8983A4-BFEF-4BB5-8766-BEDBFFC80198
P2860
Mucus-penetrating nanoparticles for vaginal drug delivery protect against herpes simplex virus.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on June 2012
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Mucus-penetrating nanoparticle ...... against herpes simplex virus.
@en
Mucus-penetrating nanoparticle ...... against herpes simplex virus.
@nl
type
label
Mucus-penetrating nanoparticle ...... against herpes simplex virus.
@en
Mucus-penetrating nanoparticle ...... against herpes simplex virus.
@nl
prefLabel
Mucus-penetrating nanoparticle ...... against herpes simplex virus.
@en
Mucus-penetrating nanoparticle ...... against herpes simplex virus.
@nl
P2093
P2860
P1476
Mucus-penetrating nanoparticle ...... against herpes simplex virus.
@en
P2093
Benjamin C Tang
Laura M Ensign
Richard Cone
Terence A Tse
Timothy Hoen
Ying-Ying Wang
P2860
P304
P356
10.1126/SCITRANSLMED.3003453
P407
P50
P577
2012-06-01T00:00:00Z